Skip to main content

Verzenio Side Effects

Generic name: abemaciclib

Medically reviewed by Philip Thornton, DipPharm. Last updated on Aug 24, 2023.

Note: This document contains side effect information about abemaciclib. Some dosage forms listed on this page may not apply to the brand name Verzenio.

Applies to abemaciclib: oral tablet.

Serious side effects of Verzenio

Along with its needed effects, abemaciclib (the active ingredient contained in Verzenio) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking abemaciclib:

More common

Less common


Other side effects of Verzenio

Some side effects of abemaciclib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to abemaciclib: oral tablet.


The most common adverse reactions (20% or greater incidence) reported across clinical trials were diarrhea, neutropenia, nausea, abdominal pain, infections, fatigue, anemia, leukopenia, decreased appetite, vomiting, headache, alopecia, and thrombocytopenia.[Ref]


Common (1% to 10%): Venous thromboembolic events, arterial thromboembolic events[Ref]

Venous thromboembolic events included deep vein thrombosis (DVT), pulmonary embolism, pelvic venous thrombosis, cerebral venous sinus thrombosis, subclavian vein thrombosis, axillary vein thrombosis, DVT inferior vena cava, device-related thrombosis, jugular vein thrombosis, catheter site thrombosis, portal vein thrombosis, hepatic vein thrombosis, jugular vein occlusion, ovarian vein thrombosis, and embolism.[Ref]


Rash included exfoliative rash, mucocutaneous rash, rash erythematous, rash follicular, rash generalized, rash macular, rash maculopapular, rash maculovesicular, rash morbilliform, rash papular, rash papulosquamous, rash pruritic, rash vesicular, and vulvovaginal rash.[Ref]

Very common (10% or more): Alopecia (up to 27%), pruritus (up to 13%), rash (up to 14%)

Common (1% to 10%): Dry skin, nail disorder[Ref]


Very common (10% or more): Diarrhea (up to 90%), nausea (up to 64%), abdominal pain (up to 35%), vomiting (up to 35%), constipation (up to 17%), stomatitis (up to 15%), dry mouth (up to 14%)

Common (1% to 10%): Dyspepsia[Ref]

Abdominal pain included upper and lower abdominal pain, abdominal discomfort, and tenderness.

Stomatitis included mouth ulceration, mucosal inflammation, and oropharyngeal pain.[Ref]


Very common (10% or more): Decreased white blood cell count (up to 90%), decreased neutrophil count (up to 88%), anemia (up to 84%), decreased lymphocyte count (up to 63%), decreased platelet count (up to 53%)

Uncommon (0.1% to 1%): Febrile neutropenia

Frequency not reported: Neutropenic sepsis[Ref]


Very common (10% or more): Increased ALT (up to 48%), increased AST (up to 37%)[Ref]


Very common (10% or more): Decreased appetite (up to 45%), decreased weight (up to 14%), dehydration (up to 10%), hypokalemia (up to 11%)[Ref]


Very common (10% or more): Arthralgia (up to 15%)

Common (1% to 10%): Muscle weakness[Ref]

Nervous system

Very common (10% or more): Headache (up to 20%), dysgeusia (up to 18%), dizziness (up to 13%)


Common (1% to 10%): Increased lacrimation[Ref]


Infections included upper respiratory tract infection, urinary tract infection, lung infection, pharyngitis, conjunctivitis, sinusitis, vaginal infection, and sepsis.[Ref]

Very common (10% or more): Infections (up to 51.2%), fatigue/asthenia (up to 65%), peripheral edema (up to 12%), pyrexia (up to 11%)

Common (1% to 10%): Influenza-like illness[Ref]


Very common (10% or more): Increased creatinine (up to 99.3%)[Ref]


Very common (10% or more): Cough (up to 19%), dyspnea (up to 12%)

Common (1% to 10%): Interstitial lung disease, pneumonitis[Ref]

Frequently asked questions


1. Product Information. Verzenio (abemaciclib). Lilly, Eli and Company. 2023.

2. Product Information. Verzenio (abemaciclib). Eli Lilly Australia Pty Ltd. 2023.

3. Product Information. Verzenios (abemaciclib). Eli Lilly and Company Ltd. 2023.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.